In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cathy Kelly

Senior Writer

Washington, DC
Cathy Kelly has been covering reimbursement and market access news for more than a decade for "The Pink Sheet" and other publications that are now part of Informa's pharmaceutical intelligence resources. Her expertise spans legislative, regulatory and public policy topics as well as coverage trends in public and private insurance markets. Cathy is especially interested in following the ongoing transformation of the US health care system and its effect upon major stakeholders in the biopharma industry. She is based in Washington D.C.
Advertisement
Set Alert for Articles By Cathy Kelly

Latest From Cathy Kelly

Annuity Payment Model For Cures May Get Test Drive In Massachusetts

First-ever implementation of often-discussed reimbursement approach for high-cost drugs would involve group of commercial payers to address “portability” issue and may start with Novartis’ Zolgensma.

 

Pricing Strategies Private Payers

Medicare Coverage For CAR-T Will Require Additional Patient Data Collection

National coverage decision does not limit Medicare payments to labeled indications or site of care. CMS expects to “leverage” existing FDA post-market data collection requirements but seeks additional data on patient-reported outcomes in some cases.

Medicare Reimbursement

Pricing Cures For Sickle Cell Disease: Sen. Cassidy Weighs In

Price decisions based on straight calculation of medical costs avoided may overestimate value of a cure, Cassidy warns.

Pricing Strategies Legislation

FDA's Real World Study On Adoption Of PD-1 Dosing Change Aims To Inform Reviewers

Study using US FDA’s Information Exchange and Data Transformation (INFORMED) program will focus on shift from weight-based to flat dosing for Opdivo and Keytruda.

Clinical Trials Research and Development Strategies

Invitation Accepted: Biopharma Leaders Will Testify At Senate Hearing On Pricing

In addition to fielding tough questions about pricing practices at the session, executives may announce new voluntary efforts to lower drug costs and will offer their own ideas for legislation.

Pricing Debate Legislation

The Rebate Effect: ‘Traditional’ Brand Costs Decline 6.5% In Commercial Plans

Lower net costs held overall spending on retail prescription drugs in employer-sponsored insurance to an increase of just 0.4% in 2018, according to the latest Express Scripts Drug Trend Report.

Pricing Debate Pharmacy Benefit Management
See All
Advertisement
UsernamePublicRestriction

Register